NeurogesX (NGSX)
NeurogesX Free Cash Flow TTM
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NGSX Free Cash Flow TTM Range, Past 5 Years
| Minimum | -45.63M | Jun 2011 |
| Maximum | 29.45M | Sep 2009 |
| Average | -20.91M |
About Free Cash Flow (TTM)
Free Cash Flow (TTM) is the sum of the last four quarters of Free Cash Flows.
For details about how YCharts calculates its quarterly Free Cash Flow numbers, click "Learn More" below.
Learn More
You may also be interested in these NGSX related companies
NGSX News
@gofigure $PPHM $NGSX $GALE short term yes, but Long term no they are not done! All have huge potential for big gains!
about 31 days ago by BiopharmaPro
about 31 days ago by BiopharmaPro
NeurogesX to Hold Conference Call to Discuss First Quarter 2012 Results
Apr 27, 9:00AM GlobeNewswire
Apr 27, 9:00AM GlobeNewswire
$ngsx Hearings are typically scheduled 30 to 45 days from the company's request
about 35 days ago by bood747
about 35 days ago by bood747
@rickz $ngsx supposed to delist tomorrow.I cant find any news on whether thye got a hearing or not.any info?
about 36 days ago by bood747
about 36 days ago by bood747
NeurogesX Receives Determination Letter From NASDAQ; Not Regaining Compliance
Apr 20, 4:06PM Benzinga
Apr 20, 4:06PM Benzinga
No i'm not kidding, 3/4 portfolio in $OCZ 1/4 BIT:ISP $PPHM $NGSX $GALE I'm all IN
about 41 days ago by micheleciani
about 41 days ago by micheleciani
$NGSX performing well today, if will go OUT in the upper part of the triangle in 1 day we go pair http://chart.ly/eutswy8
about 41 days ago by micheleciani
about 41 days ago by micheleciani
NeurogesX (NGSX) Gets FDA Acceptance for End-of-Phase 2 Meeting for NGX-1998
Apr 11, 7:33AM Street Insider
Apr 11, 7:33AM Street Insider
Wedbush Upgrades NeurogesX, Inc. (NGSX) to Outperform; Restructuring Puts NGX-1998 Liquid Formulation On Center Stage
Mar 14, 1:50PM Street Insider
Mar 14, 1:50PM Street Insider
NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Full Year 2011 Results
Feb 29, 8:30AM GlobeNewswire
Feb 29, 8:30AM GlobeNewswire
NeurogesX (NGSX) Confirms FDA Panel Did Not Recommend Approval of Qutenza
Feb 09, 5:47PM Street Insider
Feb 09, 5:47PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NGSX | 0.37 | +0.00 | +0.00% | 11.07M |
| NGPC | 6.71 | +0.03 | +0.45% | 144.49M |
| NGLS | 40.45 | -0.92 | -2.22% | 3.764B |
| NGG | 50.55 | -2.94 | -5.50% | 39.03B |
| NGB | 16.30 | +0.00 | +0.00% | |
| NFZ | 14.67 | +0.02 | +0.14% | |
| NFX | 30.56 | -1.58 | -4.92% | 4.346B |
| NFP | 13.19 | -0.12 | -0.90% | 536.26M |
| NFO | 31.54 | -0.56 | -1.73% | |
| NFLX | 67.34 | -2.10 | -3.02% | 3.848B |
